Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

53.69
-0.4100-0.76%
Post-market: 53.60-0.0900-0.17%19:52 EDT
Volume:1.85M
Turnover:98.34M
Market Cap:4.88B
PE:-9.86
High:54.32
Open:54.01
Low:52.00
Close:54.10
52wk High:71.13
52wk Low:30.04
Shares:90.95M
Float Shares:90.53M
Volume Ratio:0.98
T/O Rate:2.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.4437
EPS(LYR):-4.3416
ROE:-25.34%
ROA:-13.05%
PB:2.85
PE(LYR):-12.37

Loading ...

Crispr Therapeutics And Sirius Therapeutics Announce Multi-Target Collaboration To Develop Novel Sirna Therapies

Reuters
·
May 20

Crispr Therapeutics to Partner With Sirius Therapeutics to Develop siRNA Therapies

Dow Jones
·
May 20

CRISPR Therapeutics AG Announces Collaboration with Sirius Therapeutics to Develop Next-Gen siRNA Therapy Targeting Thrombosis

Reuters
·
May 20

Here's the most unappreciated AI beneficiary right now, according to Ark Invest's Cathie Wood

Dow Jones
·
May 19

Stock Track | CRISPR Therapeutics Soars 5% on Casgevy Sales and Strong Pipeline Prospects

Stock Track
·
May 16

Cathie Wood Dumps Palantir As Stock Touches Peak Prices, Bails On Soaring Flying-Taxi Maker Archer Aviation

Benzinga
·
May 14

Stock Track | CRISPR Therapeutics Soars 5% on Casgevy Sales and Strong Pipeline Prospects

Stock Track
·
May 13

Stock Track | CRISPR Therapeutics Soars 5% on Casgevy Sales and Strong Pipeline Prospects

Stock Track
·
May 13

Stock Track | CRISPR Therapeutics Soars Nearly 6% Pre-market on Casgevy Sales and Strong Pipeline Prospects

Stock Track
·
May 12

Stock Track | CRISPR Therapeutics Soars 5.56% in Pre-market on Commercialization Progress and Strong Pipeline

Stock Track
·
May 12

Stock Track | CRISPR Therapeutics Soars 5.56% Pre-market on Commercialization Progress and Growth Potential

Stock Track
·
May 12

Stock Track | CRISPR Therapeutics Soars 5.05% as Cathie Wood's Ark Invest Adds to Position

Stock Track
·
May 08

Crispr Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
May 08

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

Benzinga
·
May 07

Stock Track | CRISPR Therapeutics Soars 6.79% Pre-market Amid Medical AI Stock Rally and Positive Analyst Rating

Stock Track
·
May 07

Stock Track | CRISPR Therapeutics Soars 6.79% Pre-market on Chardan Capital's Buy Rating, Despite Mixed Analyst Views

Stock Track
·
May 07

Crispr Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 07

24H|Crypto Shares Gain; Canaan up 10%; Riot Platforms up 5%; Medical AI Stocks Rise; RXRX up 4%; Gold Shares Fall

Tiger Newspress
·
May 07

CRISPR Therapeutics AG reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

CRISPR Therapeutics Q1 EPS $(1.58) Misses $(1.21) Estimate, Sales $865.00K

Benzinga
·
May 07